Wockhardt Ltd (WOCKPHARMA) is currently trading at 2,078.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development. The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly. Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH. Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans. It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.

Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,086.80 and a high of ₹2,420.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Wockhardt Ltd has a market capitalization of approximately 35,441.98. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Wockhardt Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 85.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 35,441.98 Cr, Wockhardt Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Wockhardt Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 85.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Wockhardt’s upcoming earnings date is August 10, 2026, when the board is scheduled to consider Q1 FY 2026-27 unaudited results.

Wockhardt’s upcoming earnings date is August 10, 2026, for Q1 FY2026-27.

The issue price was ₹1,105 per share, which was a 4.93% discount to the floor price of ₹1,162.25 per share.

Zaynich is Wockhardt’s novel injectable antibiotic for severe drug-resistant infections, and it received US FDA approval on May 29.